Skip to main content

Table 5 Genotype and allele frequency distributions among patients with or without neuropsychiatric disorders during efavirenz based HAART

From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

Genotype

Neuropsychiatric disorders

p value

 

No

 

Yes

n

%

n

%

CYP2B6*6

*1/*1

21

42

61

44.5

0.16

*1/*6

28

56

63

46

 

*6/*6

1

2

13

9.5

 

CYP2B6*11

*1/*1

41

82

111

78.2

0.17

*1/*11

8

16

31

21.8

 

*11/*11

1

2

0

0

 

CYP2A6*9

*1/*1

39

84.8

98

79.7

0.51

*1/*9

7

15.2

22

17.9

 

*9/*9

0

0

3

2.4

 

CYP2A6*17

*1/*1

38

90.5

104

83.9

0.3

*1/*17

3

7.1

19

15.3

 

*17/*17

1

2.4

1

0.8

 

No. of CYP3A5*1 allelesa

zero

15

30

31

21.8

0.48

One

24

48

79

55.6

 

Two

11

22

32

22.5

 

ABCB1 (rs3842

*0/*0

29

63

87

65.4

0.95

*0/*1

16

34.8

43

32.3

 

*1/*1

1

2.2

3

2.3

 

ABCB1 c.3435C/T

CC

37

74

109

77.9

0.68

CT

13

26

30

21.4

 

TT

0

0

1

0.7

 

NR1I3 rs3003569CT

TT

10

21.7

29

23

0.06

TC

16

34.8

65

51.6

 

CC

20

43.5

32

25.4

 

Alleles

Frequency (%)

Frequency (%)

 

CYP2B6*6

30

32.5

0.21

CYP2B6*11

10

10.9

0.78

CYP2A6*9

7.61

11.38

0.31

CYP2A6*17

5.95

8.46

0.55

No. of CYP3A5*1 allele

46

50.4

0.56

ABCB1 rs3842

19.6

18.4

0.80

ABCB1 c.3435T

13

11.4

0.67

NR1I3 rs3003569 T

39.1

48.8

0.11

  1. P value from binary logistic regression is presented.
  2. a Haplotype analyses indicate no linkage between CYP3A5 SNPs thus subjects were grouped based on number of functional CYP3A5 allele (CYP3A5*1) for statistical analysis.